Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
- 1 October 1996
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 51 (2) , 111-116
- https://doi.org/10.1007/s002280050169
Abstract
Background: The analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment.Keywords
This publication has 0 references indexed in Scilit: